DNMT3A and cancer: The antagonistic modulation between DNMT3A and HLA class I in our study and the TCGA ECs implies that DNMT3A may be involved in epigenetic regulation of HLA class I. Previous studies support the notion that inhibition of DNA methyltransferases causes elevated HLA class I expression in several HLA class I low cancer cell lines [60–63], and functional restoration by DNA methyltransferase inhibitors is associated with transcriptomic upregulation of genes in the HLA class I antigen presentation pathway [63, 64].